An earlier study revealed that constitutive activation of B-RAFV600E mutant activates the MEK/ERK pathway and enhances melanoma cell proliferation whereas inhibition of the B-RAFV600E mutant by vemurafenib decreases melanoma cell proliferation58. This evidence concerns the gene MAP2K7 and melanoma.